10 June 2019 - At two years, advanced prostate cancer patients taking the trial drug, in addition to their standard treatment, had a 52% lower risk of cancer spread or death.

A new drug has helped reduce the risk of death by 33% in men with prostate cancer that has spread, according to the results of an international trial led by the B.C. Cancer Agency’s Dr. Kim Chi.

The double-blind study on the androgen receptor inhibitor drug called apalutamide was conducted in 23 countries at 260 cancer centres. It involved 1,052 men whose median age was 68. The study was sponsored by Janssen, the drug company who makes apalutamide.

Read Vancouver Sun article